Blood biomarker for detecting cerebral amyloid-beta deposition in cognitively normal individuals or those with mild cognitive impairment

Blood-based biomarker for early detection of cerebral amyloid-beta accumulation

This technology relates to a biomarker for the early diagnosis of cerebral amyloid-beta accumulation and associated diseases through blood tests.

Cerebral amyloid-beta accumulation progresses even before clinical symptoms appear, but a simple blood test for early detection has been lacking.

This technology's biomarker can detect cerebral amyloid-beta accumulation in the blood of cognitively normal individuals and those with mild cognitive impairment even before clinical symptoms emerge, making it a convenient and useful tool for the early diagnosis of related diseases.

‍

‍

Key Features:

• Blood-based biomarker for detecting cerebral amyloid-beta accumulation
• Early detection before clinical symptom onset
• Applicable to cognitively normal individuals and those with mild cognitive impairment
• Facilitates early diagnosis of related diseases through a simple blood test